Interesting read. This is the conclusion to the post:
"We believe that, given the high placebo response rate in the recently completed trial, the company will conduct a thorough review of their trial protocols and procedures to ensure that the placebo response rate in future trials is more in-line with those seen from the Linzess trials. Plecanatide is an approvable drug but whether or not the recently completed trial will count as a registration trial remains an open question until the FDA provides input.
Investors who seek a long term investment in SGYP should look to the company to provide further details on plecanatide's regulatory pathway once the company receives minutes from their end of phase 2 review meeting. There has been much speculation that the company is being groomed for acquisition. Given the company's $420 million market capitalization, and given that plecanatide is potentially a blockbuster drug and SP-333, once further developed, is potentially a novel treatment for ulcerative colitis, it is likely that the company will continue developing these drugs on it's own until the stock price more fully reflects the market potential of its pipeline. In other words a deal in the near term is, in our view, unlikely because the company is undervalued and management knows it."
Regarding exit strategies your way off base .. MGMT is the one who highlighted they wanted to be acquired in the last quarter. Your post is nothing but a fear / scare tacitc.I suspect your an alias for red acre.